据央视新闻，当地时间22日傍晚，伊朗卫生部发言人侯赛因·克尔曼普尔通过其社交账号表示，多年 前，伊朗卫生部就在靠近核设施的医疗机构设置了核应急急救中心。当天在美军轰炸后被送往这些中心 的伤员中，无人出现放射性污染迹象。美总统特朗普美东时间21日宣布，美军"成功打击"伊朗福尔多、 纳坦兹和伊斯法罕三处核设施。 ...

Core Viewpoint - The insurance industry has significantly accelerated its capital replenishment efforts in 2023, with a total of 69.213 billion yuan raised through capital increases and bond issuances, marking a 95% year-on-year increase [1] Group 1: Capital Replenishment Statistics - As of June 22, 2023, insurance companies have collectively raised 69.213 billion yuan through capital increases and bond issuances, with at least six companies approved for capital increases totaling approximately 8.853 billion yuan [1] - Twelve insurance companies have issued capital replenishment bonds or perpetual bonds, amounting to a total bond issuance of 60.36 billion yuan [1] - The approved capital increases for China Post Life Insurance and China United Insurance totaled 5.18 billion yuan, with China Post Life increasing its registered capital from 28.663 billion yuan to 32.643 billion yuan and China United Insurance from 2.9 billion yuan to 4.1 billion yuan [1] Group 2: Reasons for Increased Capital Replenishment - The implementation of stricter capital recognition rules under the second phase of the solvency regulatory framework has led to a decline in the solvency adequacy ratio for many insurance companies, necessitating capital replenishment through increases or bond issuances [2] - Continuous declines in interest rates have put pressure on insurance companies' liability reserves and solvency adequacy ratios, prompting the need for external capital replenishment to maintain sufficient solvency levels [2] - The insurance industry is undergoing deep adjustments and transformations, requiring companies to enhance their competitiveness and risk prevention capabilities through capital replenishment [2] Group 3: Diverse Capital Supplementation Methods - The insurance industry is exploring various capital replenishment methods, including zero-interest convertible bonds and capital reserve transfers to increase registered capital [3] - China Ping An has issued zero-interest convertible bonds worth approximately 11.765 billion Hong Kong dollars, which are convertible into H-shares, optimizing its capital structure and providing funding support for business development [3] - Dinghe Property Insurance announced plans to increase its registered capital from approximately 4.643 billion yuan to 6 billion yuan through capital reserves, maintaining the shareholding ratio of existing shareholders [3] Group 4: Future Trends - The trend of capital increases and bond issuances in the insurance industry is expected to be influenced by various factors, including business needs, strategic planning, and regulatory policy changes [3] - Overall, the trend of capital replenishment in the insurance industry is projected to show stable growth through 2025, with companies needing to consider market conditions, regulatory policies, and their operational status during the process [3]

本报记者 杨洁 6月22日，内地与香港快速支付系统互联互通（以下简称"跨境支付通"）正式上线。《证券日报》记者获悉，作为境内首 批试点行，多家银行积极落地跨境支付通业务，为内地和香港两地居民提供跨境实时汇款服务。 业内人士表示，跨境支付通不仅解决了传统跨境支付的效率与成本痛点，更成为推动人民币国际化、深化内地与香港金融 合作的战略抓手。下一步，商业银行可以以跨境支付通为切入点，加速技术迭代和优化服务模式，为中国金融开放和全球支付 体系变革贡献力量。 助力金融高水平开放 "随着内地与香港往来日益密切，经贸合作更加频繁，居民南下北上消费需求旺盛，对跨境支付的高效安全以及资金的快 速流通提出了更高要求。"中国人民银行有关部门负责人在答记者问时表示，中国人民银行聚焦跨境支付需求，联合香港金融 管理局开展内地网上支付跨行清算系统与香港快速支付系统"转数快"互联互通，充分发挥监管合力和系统优势，打通资金清算 渠道，提高支付效率、降低交易成本，促进两地经贸活动与人员往来，助力金融高水平开放，进一步巩固和提升香港国际金融 中心地位。 据悉，与传统跨境汇款相比，跨境支付通有效缩短了跨境汇款链路，提高了跨境汇款效率，从技术上支持 ...

Core Viewpoint - The recent draft of the "Securities Company Classification Evaluation Regulations" aims to shift the focus of the industry from "scale competition" to "quality competition," promoting differentiated development paths for small and medium-sized institutions [1][2] Group 1: Industry Role and Function - Securities firms play a crucial role in China's capital market and financial system, facilitating a healthy investment and financing cycle, serving the real economy, national strategies, and wealth management for residents [1] - The classification results show a stable number of firms across categories, with A, B, and C class companies accounting for 50%, 40%, and 10% respectively, and approximately 14 firms maintaining an AA rating [1] Group 2: Regulatory Changes and Focus - The revised regulations emphasize guiding securities firms to enhance their functional roles and professional capabilities, with a new evaluation framework focusing on risk management, compliance, business development, and functional performance [2] - A new "functional performance" evaluation organized by the China Securities Association will be incorporated into the classification evaluation to better assess firms' contributions [2] Group 3: Business Development and Performance Metrics - The regulations remove the revenue-based scoring system and increase the emphasis on net asset return, raising the maximum score from 1 to 2 points, encouraging firms to focus on efficiency and quality rather than just scale [4][5] - The projected net asset return for the securities industry in 2024 is 5.5%, a 0.7 percentage point increase year-on-year, with firms like Dongfang Caifu leading at 12.6% [4] Group 4: Differentiated Development for Small and Medium-sized Firms - The regulations expand the scoring criteria for net asset return and major business income from the top 20 to the top 30 firms, allowing smaller firms to explore differentiated development paths [5] - Small and medium-sized firms are encouraged to focus on high-end wealth management and specific industry sectors to create specialized advantages and provide tailored financing solutions [5][6] Group 5: Encouragement of Long-term Investment - The regulations also introduce new indicators to promote long-term capital inflow, including metrics for self-investment in equity assets and management of equity fund products, encouraging firms to enhance their contributions to long-term wealth management [6]

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, related to misleading statements about its clinical trials and the safety of its gene therapy product RP-A501 [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals provided misleading information regarding the safety and clinical trial protocol of RP-A501, particularly concerning serious adverse events, including participant deaths [3][4]. - On May 27, 2025, the U.S. FDA placed a clinical hold on the RP-A501 Phase 2 study after a patient suffered a serious adverse event, which was not disclosed to investors prior to the protocol amendment [4]. Group 2: Lead Plaintiff Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek appointment as lead plaintiff, representing the interests of the class [5]. - The lead plaintiff is typically the investor with the greatest financial interest in the case and can select a law firm to litigate the lawsuit [5]. Group 3: Company Background - Rocket Pharmaceuticals operates as a late-stage biotechnology company focused on developing gene therapies for rare diseases [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

哈梅内伊高级顾问：即便核设施被摧毁 游戏也远未结束 智通财经6月23日电，据央视新闻，伊朗最高领袖哈梅内伊的高级顾问阿里·沙姆哈尼当地时间22日傍晚 在社交媒体上发文称，即使伊朗核设施被摧毁，游戏也远未结束。浓缩（铀）材料、知识储备和政治意 志依然存在。"凭借正当防卫权，善于谋略、避免盲目打击的一方将掌握政治与行动主动权。好戏还在 后头！"6月13日，沙姆哈尼在以军对伊朗的袭击中受重伤，此后有媒体报道称其已于14日死亡。6月21 日，沙姆哈尼本人在社交媒体上发文否认身亡传闻。 ...

Core Insights - The global obesity drug market is projected to exceed $100 billion by 2030, driven by the increasing number of obese individuals worldwide [1][2] - Major pharmaceutical companies, both multinational and domestic, are intensifying their efforts in the obesity drug sector, leading to fierce competition in technology, capital, and market presence [2] Domestic Drug Development - Domestic companies are making significant progress in the development of obesity drugs, with recent approvals for clinical trials of GLP-1 class innovative drugs by Changshan Biochemical Pharmaceutical and Guangdong Zhongsheng Pharmaceutical [3] - Changshan Biochemical has received approval for clinical trials of its injection for weight loss, while Guangdong Zhongsheng has completed the first participant enrollment for its innovative peptide drug RAY1225 in a Phase III trial [3] - The global sales of GLP-1 receptor agonists (GLP-1RA) are expected to exceed $150 billion by 2031, indicating a strong market potential [3] Market Dynamics - The global obesity drug market is currently dominated by Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, with semaglutide projected to generate sales of 6.6 billion yuan in China by 2024 [4] - The domestic GLP-1 drug market is expected to surpass 20 billion yuan by 2030, with several domestic GLP-1 drugs already approved [5] - The influx of domestic companies into the obesity drug market reflects a consensus on the explosive growth potential of the sector, although it may lead to intensified price competition [5] Competitive Landscape - Chinese pharmaceutical companies are leveraging multi-target innovation and differentiated development strategies to gain a competitive edge in the GLP-1 market [6] - Jiangsu Hengrui Medicine's dual-target drug HRS9531 has shown superior weight loss results compared to existing treatments, indicating the potential for domestic products to compete internationally [6] - Cross-border collaborations in the GLP-1 field are increasing, with companies like Federated Pharmaceutical and Hansoh Pharmaceutical engaging in licensing agreements to expand their market reach [6][7] Future Outlook - The obesity drug market is expected to undergo a significant reshuffle in the next 3 to 5 years, with products that demonstrate clinical value and technological barriers likely to prevail [7]

本报记者 袁传玺 近日，国际数据公司IDC发布的《中国2024年AI数字人市场份额》报告显示，2024年中国AI数字人市场规模约41.2亿元， 同比增长85.3%，实现高速增长。 国内AI数字人市场的高速增长，离不开技术的进步。在生成式AI与大模型技术浪潮下，2025年，AI数字人正以前所未有的 速度从概念走向规模化应用，成为产业数字化转型进程中的焦点与新引擎。 百度集团股份有限公司（以下简称"百度"）副总裁、电商总经理平晓黎表示，今年4月份百度发布的高说服力数字人已让 数字人进入3.0时代，标志着智能电商迈入新篇章，新一代高说服力数字人成为了一个"形神音容"高度协调、会思考决策、能协 作完成特定任务的超级智能体。 AI数字人加速普及 以百度高说服力数字人为例，百度研制的多模协同的数字人技术，基于文心4.5T实现了融合多模规划与深度思考的剧本生 成，由剧本驱动数字人多模协同，实现动态决策的实时交互，使数字人的"神、形、音、容、话"达到高度统一，最终呈现出一 个具备高表现力、内容吸引人、"人—物—场"可自由交互的超拟真数字人。 平晓黎表示，百度的罗永浩数字人已达到媲美头部主播的体感效果，随着大模型与多模能力发展 ...

本报记者 田鹏 日前，上海数据交易所与上海交通大学上海高级金融学院在中国企业数据价值化高峰论坛上共同发布"上市公司数据价值 化研究榜单"，为市场提供全新的、前瞻性的评价视角。作为国内首个系统性评价上市公司数据价值化进程的研究成果，榜单 分为数据资源入表上市公司100强和数据资源未入表上市公司100强，同时按照行业、地区等维度做了区分。 "本次榜单的发布有助于明晰数据资产化的发展方向，为行业实践提供重要参考与指引。"上海数据交易所总经理汤奇峰在 接受《证券日报》记者采访时表示，通过榜单不仅能够识别出在数据资产化工作中处于领先地位的企业，还能借此剖析其面临 的挑战，为其他企业未来的发展提供可借鉴的示范路径。同时，鉴于上市公司在市场中具有重要的标杆作用，该榜单亦从侧面 反映了作为中国数字经济重要主体的上市公司在推动数字经济发展中的贡献，以及其在数据要素化、产品化和资产化过程中的 发展情况。 值得关注的是，此次发布的榜单不仅对已实现数据资产入表企业的价值化程度进行了评估，还特别评选出100家未入表企 业的数据价值化程度，以便更全面地洞察整个市场在数据价值化进程中的发展态势。 榜单结果显示，万达信息股份有限公司（以下简 ...

Group 1 - The article discusses the author's journey into investing, starting in high school in 2011, focusing on REITs, preferred stocks, and high-yield bonds, indicating a long-standing interest in markets and the economy [1] - The author has recently adopted a strategy that combines long stock positions with covered calls and cash secured puts, emphasizing a fundamental long-term investment approach [1] - The author primarily covers REITs and financials on Seeking Alpha, with occasional articles on ETFs and other stocks influenced by macro trade ideas [1]